Shumet Hailu

Shumet Hailu is an experienced pharmaceutical professional currently serving as the Senior Director of CMC at Cardiff Oncology since June 2023. Previously, Shumet held the position of Director of Drug Product Development and Manufacturing at Turning Point Therapeutics from November 2020 to May 2023, where responsibilities included leading drug product development, authoring CMC regulatory sections, and conducting pediatric formulation development for Repotrectinib. Prior experience includes roles as Associate Director of Drug Product Development and Manufacturing at Allergan, overseeing multiple clinical projects and formulation development for UBRELVY™, and as a Senior Scientist at Takeda Oncology, where Shumet aided in advancing several oncology products, including NINLARO®. Shumet holds a Ph.D. in Pharmaceutical Sciences from the University of Connecticut, an M.Sc. in Pharmaceutics, and a Bachelor’s degree in Pharmacy from Addis Ababa University.